I am participating or have participated in a clinical trial
You are participating or have participated in a clinical study on lymphoma? The LYSA/LYSARC thanks you again for your trust and for your help in advancing research on these diseases.
You will find below summaries of the results of the LYSA/LYSARC studies that are completed.
You will also find information on potential reuses of your data and biological samples in further research on lymphoma.
The LYSA/LYSARC, responsible for the data processing in these analyses, processes your data in accordance with the CNIL guidelines and the European Data Protection Regulation (GDPR) to ensure its security.
It is not possible to identify you through data collected for research purpose: your name is substituted by a code. Please, remember that you have a right to access and rectify your data, to limit any processing of your data and to complain to a supervisory authority.
The data used in the study in which you have agreed to participate cannot be deleted as they contribute to the achievement of the research objectives. However, you may object to its reuse in new programs. If you object to the reuse of your personal data, or to the reuse of your biological samples, or if you wish additional information, we invite you to contact your doctor, who will contact LYSA/LYSARC while maintaining your anonymity. You may also, as a second option, contact the LYSA/LYSARC data protection officer at: firstname.lastname@example.org.
The data collected during the study are stored securely until the study centers are closed and the final research report is published or until two years after the last publication of a new analysis. They are then archived for 25 years.
The data processing performed by LYSA/LYSARC is based on Articles 6 (public interest mission) and 9 (health data processing for scientific research purposes) of the EU Regulation 2016/679 (General Data Protection Regulation (GDPR)).
- All studies
- Closed to inclusions
- Essai de phase 1
- Follicular lymphomas
- Lymphomes de Hodgkin
- Phase 3 trial
- Study in progress